Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Non-Valvular Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT02756481

CV185-333

Details and patient eligibility

About

To characterize treatment patterns and healthcare resource utilization among adults diagnosed with non-valvular atrial fibrillation (NVAF) from the private setting in Venezuela.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with diagnosis of AF (incident and prevalent cases)
• Patient with at least 18 years
• Patients enrolment before and during the study period
• Patients treated in Venezuela

Exclusion criteria

• Women who were pregnant at any moment during the study period

Trial design

80 participants in 1 patient group

NVAF Treatment patterns

Description:

Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit. Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected: * Type of treatment, start \& stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable * Type of therapy utilized (monotherapy/combination therapy) * Total number of therapy changes or switches through the course of treatment * Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR) * Routine care (visits per month) by anticoagulation regimen